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BACKGROUND. The objective of this study was to characterize changes in hemo-
globin (HGB) levels after the initiation of androgen-deprivation therapy (ADT) in
patients with previously untreated, metastatic prostate cancer who were enrolled
in a large clinical trial.
METHODS. The multivariate associations between 3-month change in HGB and
baseline characteristics were evaluated with a linear regression model. The asso-
ciations between 3-month change in HGB level and time-to-event outcomes,
including overall survival and progression-free survival, were evaluated by using
proportional hazards regression models.
RESULTS. Quartiles of baseline HGB levels were 12.0 g/dL, from 12.1 to 13.7 g/
dL, from 13.8 to 14.7 g/dL, and >14.7 g/dL. Overall, 3 months after initiating ADT,
the mean HGB level declined 0.54 g/dL (standard deviation [SD], 1.68 g/dL); how-
ever, the mean HGB level increased by 0.99 g/dL (SD, 1.83 g/dL) in patients who
had baseline HGB levels <12 g/dL and decreased 1.04 g/dL (SD, 1.28 g/dL) in
patients who had baseline HGB levels 12 g/dL. After adjusting for potential con-
founders, including baseline HGB level, a decline in HGB after 3 months of ADT
was associated independently with shorter survival (hazards ratio [HR], 1.10 per
1 g/dL decline; P ¼ .0035) and shorter progression-free survival (HR, 1.08 per 1 g/dL
decline; P ¼ .013). An unexpected finding was that the effect of baseline HGB on
overall and progression-free survival varied significantly by race.
CONCLUSIONS. In a sample of men with newly diagnosed, metastatic prostate can-
cer, a decline in HGB level after 3 months of ADT was associated with shorter
survival and progression-free survival after adjusting for disease status and other
baseline covariates. Although race alone was not a strong predictor of death
or disease progression, the effect of the baseline HGB level on overall and
progression-free survival varied significantly by race. Cancer 2006;107:489–96.
 2006 American Cancer Society.
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I n a previous study, we showed that anemia was common amongpatients with newly diagnosed, metastatic prostate cancer (25% of
patients presented with hemoglobin levels <12 g/dL) and that ane-
mia prior to the initiation of treatment was associated with shorter
survival, shorter progression-free survival, and lower likelihood of
prostate-specific antigen (PSA) normalization after adjusting for dis-
ease status and other covariates.1 Anemia is a described adverse
effect of androgen-deprivation therapy (ADT). In a group of patients
with largely nonmetastatic prostate cancer and normal mean hemo-
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globin levels at baseline, ADT was associated with a
significant decline in hemoglobin after the initiation
of therapy.2 Similar results were reported recently by
Japanese investigators.3
Relatively little is known about the change in
hemoglobin in anemic patients who are starting ADT
for advanced prostate cancer. Anemia may be ex-
pected to worsen to the extent that therapy-induced
hypogonadism reduces red cell production, but it
also may improve as a result of successful cancer
treatment.
The clinical significance of hemoglobin change
after initiation of hormone therapy remains poorly
defined. Recently, D’Amico et al. reported that a
decline in hemoglobin of 1 g/dL during the first
month of neoadjuvant ADT was a predictor of early
recurrence in patients who received neoadjuvant
ADT followed by radiation for high-risk, localized
prostate cancer.4 The prognostic or predictive value
of hemoglobin change after initiation of hormone
therapy for metastatic prostate cancer is not known.
We hypothesized that a change in hemoglobin
level after the initiation of therapy may be heteroge-
neous in patients with advanced prostate cancer and
may be an independent prognostic factor in advanced
prostate cancer. The objective of the current study was
to characterize this change by reviewing hemoglobin
levels, relevant covariates, and outcome data from the
Southwest Oncology Group (SWOG) 8894 trial, a ran-
domized study that compared orchiectomy alone with
orchiectomy plus the antiandrogen flutamide in the
initial treatment of metastatic prostate cancer.
MATERIALS AND METHODS
Patients
SWOG Study S8894 (Intergroup Study 0105) exam-
ined orchiectomy with or without antiandrogen (flu-
tamide) in men with metastatic prostate carcinoma
in a randomized, double-blinded, Phase III trial. Be-
tween 1989 and 1994, 1286 patients were enrolled.
Inclusion criteria were histologically proven diagnosis
of adenocarcinoma of the prostate with bone or dis-
tant soft tissue metastases. Adequate hematologic,
hepatic, and renal functions were required. Eligible
patients were required to have a SWOG performance
status of 0 to 3, although a performance status of
3 was allowed only if bone pain was the cause of
incapacitation. Measurable disease was not required.
Prior or concomitant hormone therapy, chemother-
apy, or biologic response, modifiers were not allowed.
Baseline studies included evaluations of renal,
hepatic and hematologic function as well as history,
physical examination, serum PSA measurement, and
central pathologic review with Gleason grading of
biopsy specimens. On study, physical examinations
and laboratory tests, including hemoglobin measure-
ments, occurred after 1 month and after 3 months of
treatment and every 3 months thereafter. At baseline
and at 6-month intervals up to 2 years, the extent of
disease was evaluated by bone scan. After 2 years, a
bone scan was performed only if the PSA level in-
creased by 25 ng/mL during any 3-month period.
Patients were followed for survival. Results of the pri-
mary treatment plan were reported previously by
Eisenberger and colleagues.5 All patients signed an
Institutional Review Board-approved informed con-
sent form.
Statistical Methods
Associations between 3-month changes in hemoglo-
bin levels and various baseline characteristics were
evaluated by using multivariate linear regression. The
baseline characteristics examined included baseline
hemoglobin level (g/dL), the presence of bone pain
(yes vs. no), performance status (0–1 vs. 2–3), extent
of disease (minimal disease was defined as metas-
tases to lymph nodes and/or to the axial skeleton,
extensive disease was defined as metastases to vis-
cera or the appendicular skeleton), Gleason sum (5
vs. 6–7 vs. 8–10), treatment assignment (flutamide vs.
placebo), age, PSA, prior local radiation therapy, prior
prostatectomy, and race. In addition, t tests were
used to evaluate the association of change in hemo-
globin with treatment assignment (flutamide vs. pla-
cebo), race (African American vs. other), and baseline
anemia (hemoglobin <12 g/dL).
The associations between 3-month change in
hemoglobin level and time-to-event outcomes, in-
cluding overall survival and progression-free survival,
were evaluated by using proportional hazards regres-
sion models with adjustment for the baseline charac-
teristics detailed above. Day 0 in these survival
models was defined as 3 months postregistration.
Patients who died or progressed within the 3 months
postregistration were excluded from the analysis. To
explore whether the correlation between hemoglobin
level and outcome differed by race, interaction terms
were added to these models.
RESULTS
Anemia Prevalence and Patient Characteristics
Of 1286 patients registered to this study, 827 patients
were eligible and had data available for all of the
variables analyzed. Of these, 2 patients died within
3 months of registration, and 8 experienced disease
progression/recurrence before their follow-up hemo-
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globin measurement. Those 10 patients were ex-
cluded, leaving 817 patients available for the current
analysis. Overall survival and progression-free survi-
val were comparable between patients who were
included and patients who were excluded from the
analysis, suggesting that covariate data were missing
at random. Hemoglobin and Gleason score measure-
ments were missing most frequently. The patients
who were included in the analysis are described
briefly in Table 1.
The median pretreatment hemoglobin level was
13.7 g/dL. Quartiles of baseline hemoglobin were dis-
tributed as follows: first quartile (Q1), 12.0 g/dL;
Q2, 12.1 to 13.7 g/dL; Q3, 13.8 to 14.7 g/dL; and Q4,
>14.7 g/dL. After 3 months of treatment, the median
hemoglobin level was 12.8 g/dL, with the following
quartile distribution: Q1, 11.8 g/dL; Q2, 11.9 to 12.8
g/dL; Q3, 12.9 to 13.8 g/dL; and Q4, >13.8 g/dL. The
baseline hemoglobin level was not correlated with
the baseline serum testosterone level (testosterone
data were available for 599 patients).
Change in Hemoglobin after 3 Months of Therapy
Overall, the mean change in hemoglobin between
baseline and 3-month follow-up was a decrease of
0.54 g/dL (standard deviation, 1.68 g/dL). There was
considerable variability with regard to hemoglobin
change after the initiation of therapy, as indicated by
the standard deviation. A multivariate linear regres-
sion model was fit with 3-month change in hemoglo-
bin level as the outcome. Higher baseline hemoglobin
concentration (g/dL), flutamide treatment, black race,
worse performance status, increasing age, and prior
radiation therapy were associated with a 3-month
decline in hemoglobin level. The remaining covari-
ates had no significant effect, and no covariate was
associated with an increase in hemoglobin level
(Table 2).
The association of change in hemoglobin with
baseline hemoglobin, race, and flutamide treatment
is illustrated in detail in Table 3. Briefly, hemoglobin
increased in patients with baseline anemia and de-
creased in patients without baseline anemia. In pa-
tients without anemia at baseline, treatment with
flutamide was associated with a greater decline in
TABLE 1
Descriptive Table of 817 Patients from S8894 Included
in This Analysis
Characteristic All patients
African American (%) 19.8
Bone pain (%) 48.0
Performance status 2–3 (%) 15.2





Age at study entry, y (mean 6 SD) 69.6 6 8.0
PSA at study entry (mean 6 SD) 637 6 1251
Prior radiation to the primary tumor (%) 18.7
Prior radical prostatectomy (%) 13.5
Baseline Hgb
Mean 6 SD 13.3 6 2.1
Median 13.7
Hgb at 3 months postregistration
Mean 6 SD 12.7 6 1.6
Median 12.8
3-Month Hgb change (mean 6 SD)  0.54 6 1.68
SD indicates standard deviation; Hgb, hemoglobin.
TABLE 2
Multivariate Analysis Predicting 3-Month Change in Hemoglobin
Variable Coefficient (SE)* P
African-American  0.64 (0.12) <.0001
PSA (ng/mL) in 20-unit increments 8.1E-4 (7.2E-4) .26
Bone pain 0.071 (.090) .43
Performance status 2–3 vs. 0–1  0.36 (.13) .0057
Extensive disease 0.060 (.11) .58
Age in 5-y increments  0.073 (0.027) .0080
Prior RT to primary tumor  0.25 (.12) .031
Prior RP  0.22 (.13) .093
Gleason score
<5 0 (Reference)
6–7  0.13 (.17) .45
8–10  0.14 (.16) .38
Flutamide treatment  0.54 (.09) <.0001
Baseline hemoglobin (g/dL)  0.56 (.02) <.0001
SE indicates standard error; PSA, prostate-specific antigen; RT, radiotherapy; RP, radical prostatectomy.
* Coefficients are the 3-month change in hemoglobin associated with a 1-unit increase in the corre-
sponding variable.
TABLE 3
Association of Change in Hemoglobin with Cross-Classification of
Baseline Hemoglobin, Race, and Flutamide Treatment
Variable
3-Month change in hemoglobin
Baseline < 12 g/dL P Baseline  12 g/dL P
Race
Black þ 0.69 (1.76) .039*  1.04 (1.40) .97*
Not black þ 1.20 (1.86)  1.05 (1.26)
Flutamide treatment
Yes þ 0.84 (1.87) .18*  1.38 (1.26) <.001*
No þ 1.16 (1.78)  0.71 (1.21)
Overall þ 0.99 (1.83) —  1.04 (1.28) <.001y
* Within baseline hemoglobin group.
y Across baseline hemoglobin groups.
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hemoglobin. Black race had no effect on change in
hemoglobin in patients without anemia at baseline
but was associated with less recovery of hemoglobin
in patients who were anemic at study entry.
Association between Hemoglobin Change in the First
3 Months and Clinical Endpoints
We previously reported that baseline anemia is an
important adverse prognostic factor for both overall
and progression-free survival in patients with newly
diagnosed metastatic prostate cancer. The current
analysis showed that 3-month change in hemoglobin
is a new prognostic factor in a multivariate analysis
that included baseline hemoglobin and a number of
other traditional risk factors, including performance
status, Gleason score, and disease extent. In this
analysis, a decline in hemoglobin after 3 months of
ADT was independently associated with shorter sur-
vival (hazards ratio [HR], 1.10 per 1 g/dL decline;
P ¼ .0035) and shorter progression-free survival (HR,
1.08 per 1 g/dL decline; P ¼ .013). Thus, both base-
line hemoglobin and 3-month hemoglobin change
are prognostic, even after taking into account these
other risk factors. Compared with Q4 (an increase in
hemoglobin by >0.3 g/dL), patients in Q1 (a drop in
hemoglobin by 1.6 g/dL) had a 31% higher risk of
death. Thus, the impact of hemoglobin change on
the risk of death and early progression was moderate
but was sufficiently large to be important clinically
(Tables 4, 5).
Another novel observation of the current analysis
is that there was a modest but important difference
between the races with regard to the observed asso-
ciations between hemoglobin and clinical outcomes.
Although we did not observe that race modified the
association between 3-month hemoglobin change
and either overall survival or progression-free survi-
val, the interaction between race and baseline hemo-
globin was significant for both outcomes (P < .04).
This model suggests that the difference in overall
survival across races depended on baseline hemoglo-
bin levels. In Table 4, the HR for death of 0.81 be-
tween blacks and nonblacks was among patients
who had baseline hemoglobin levels of 13.7 g/dL.
Among patients who had baseline hemoglobin levels
of 11.7 g/dL, the HR for death may be calculated as
0.81*0.90(11.7–13.7) ¼ 1.0, where 0.90 is the interaction
effect shown in Table 4. Below this level of baseline
hemoglobin, black patients had worse overall survival
than their nonblack counterparts, although this dif-
ference was significant only at hemoglobin levels
<7.8 g/dL. At hemoglobin levels >11.7 g/dL, black
patients had better overall survival than their non-
black counterparts, but this difference was significant
only at hemoglobin levels >14.2 g/dL. This interac-
tion also was observed for progression-free survival,
for which the black:nonblack HR was 1.0 at a base-
line hemoglobin level of 11.1 g/dL. Below this level,
TABLE 4
Multivariate Analysis of Prognostic Factors for Overall Survival
Variable HR for death 95% CI P
African American 0.81 0.63–1.03 .081
PSA (ng/mL) in 20-unit increments 1.00 0.999–1.001 .53
Bone pain 1.55 1.33–1.80 <.0001
Performance status 2–3 vs. 0–1 1.18 0.96–1.46 .12
Extensive disease 1.50 1.25–1.80 <.0001
Age in 5-y increments 1.04 1.00–1.10 .076
Prior RT to primary tumor 0.97 0.80–1.18 .74
Prior RP 0.70 0.56–0.88 .0021
Gleason score
<5 1.0 Reference
6–7 1.26 0.94–1.68 .12
8–10 1.68 1.27–2.22 .0002
Flutamide treatment 0.86 0.74–0.99 .040
Baseline hemoglobin centered
at 13.7 g/dL (1-unit increment) 0.88 0.83–0.93 <.0001
3-Month hemoglobin change
(g/dL) (1-unit decrement) 1.10 1.03–0.16 .0035
African American baseline hemoglobin 0.90 0.82–0.98 .017
HR indicates hazard ratio; 95% CI, 95% confidence interval; PSA, prostate-specific antigen; RT, radio-
therapy; RP, radical prostatectomy.
TABLE 5





or death 95% CI P
African American 0.79 0.62–1.00 .051
PSA (ng/mL) in 20-unit increments 0.999 0.998–1.000 .25
Bone pain 1.52 1.30–1.77 <.0001
Performance status 2–3 vs. 0–1 1.06 0.86–1.32 .58
Extensive disease 1.53 1.28–1.84 <.0001
Age in 5-y increments 1.01 0.96–1.06 .73
Prior RT to primary tumor 0.93 0.77–1.14 .49
Prior RP 0.75 0.60–0.93 .011
Gleason score
<5 1.0 Reference
6–7 1.23 0.92–1.64 .16
8–10 1.74 1.32–2.30 <.0001
Flutamide treatment 0.86 0.74–1.00 .043
Baseline hemoglobin centered
at 13.7 g/dL (1-unit increment) 0.87 0.83–0.92 <.0001
3-Month hemoglobin change
(g/dL) in 1-unit decrement 1.08 1.02–1.15 .013
African American baseline hemoglobin 0.91 0.84–1.00 .038
HR indicates hazards ratio; 95% CI, 95% confidence interval; PSA, prostate-specific antigen; RT,
radiotherapy; RP, radical prostatectomy.
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black patients had worse progression-free survival
than their nonblack counterparts, although this dif-
ference never achieved significance. At hemoglobin
levels >11.1 g/dL, progression-free survival among
black patients was better than that among nonblack
patients, and this difference became significant at
baseline hemoglobin levels >13.7 g/dL. These com-
plex correlations are illustrated in Figure 1.
DISCUSSION
The baseline hemoglobin level was an independent
determinant of 3-month change in hemoglobin after
initiation of ADT, as we hypothesized. Although over-
all hemoglobin levels declined with ADT initiation,
this masked the finding that hemoglobin levels
increased in patients who were anemic prior to ther-
apy and decreased in patients with no anemia at
baseline. We cannot exclude the possibility that a
portion of this observation represents regression to
the mean, but this observation also is consistent with
the hypothesis that, in patients with more severe,
cancer-associated anemia, the salutatory effects of
successful cancer treatment exceed the reduction in
hemoglobin level caused by androgen loss. In addi-
tion to baseline hemoglobin, a multivariate analysis
identified flutamide treatment, black race, worse per-
formance status, increasing age, and prior radiation
therapy as statistically significant factors (P < .05) that
were associated with a 3-month decline in hemoglo-
bin level. It is not surprising that elderly patients or
those with a poor performance status may be at greater
risk of treatment-associated anemia. Similarly, prior
radiation therapy may reduce the bone marrow re-
serves needed to maintain hemoglobin in a hypogo-
nadal state. Flutamide may be associated with a greater
drop in hemoglobin caused by greater suppression of
androgen signaling. Hemolotic anemia also rarely
has been reported in association with flutamide ther-
apy (Eulexin Prescribing Information).
The current results provide additional evidence
of a link between anemia and poorer outcomes in
patients with advanced prostate cancer. In addition
to pretreatment anemia, which was identified pre-
viously as an adverse prognostic factor, this is the
first report to our knowledge demonstrating that a
decline in hemoglobin after 3 months of hormone
therapy independently predicts a shorter survival and
progression-free survival. It is noteworthy that our
results are consistent with the findings of D’Amico
et al., who showed that a decline in hemoglobin dur-
ing the first month of neoadjuvant ADT was asso-
ciated with a higher risk of early disease recurrence
after combined treatment with ADT and radiation
therapy.4 Thus, a change in hemoglobin level after
the initiation of ADT may be a clinical sign of more
aggressive disease, or it may contribute to resistance
to therapy not only in early stages but also in meta-
static prostate cancer.
The pathophysiology behind this observation
merits further study. Anemia may lead to therapy
resistance either directly or by association. Anemia-
related tumor hypoxia may contribute to treatment
resistance. An association between anemia and
tumor hypoxia has been demonstrated in breast can-
cer,6 cervical cancer,7 and others. In addition,
hypoxia has been observed in the prostate of rats
that received ADT.8 Tumor hypoxia has been impli-
FIGURE 1. Hazards ratio (HR) estimates (dotted-and-dashed line) are
shown for black patients versus nonblack patients (with all other predictive
variables the same) across the range of baseline hemoglobin levels seen in
this data set. The 95% confidence interval bands (solid lines) also are given,
and a reference HR of 1.0 is shown with a dotted line. Regions in which the
bands do not include 1.0 indicate a significant race effect.
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cated in prostate cancer resistance to apoptosis9 as
well as resistance to radiation therapy 10 and che-
motherapy.11 Cellular response to hypoxia may med-
iate resistance to androgen deprivation. Thus, a
possible interpretation of these results is that andro-
gen resistance in these patients is influenced by ane-
mia-related tumor hypoxia.
Another possible explanation is that anemia and
androgen resistance share a common pathophysiol-
ogy. Several cytokines have been associated with ane-
mia of chronic disease, including interleukin 1 (IL-1),
IL-6, IL-12, tumor necrosis factor (TNF), transform-
ing growth factor b (TGFb), interferon-a, interferon-
b, and interferon-g.12,13 Many of the same cytokines
also may promote androgen resistance and the
growth of prostate cancer metastases in the bone
microenvironment.14 One example is IL-6, which
may contribute to the development of androgen
resistance.15 IL-6 is secreted by androgen-indepen-
dent prostate cancer (AIPC) cells, is found at elevated
levels in the blood of patients with AIPC,16 and pro-
duces an autocrine mitogenic signal in these cells.17
Similarly, it has been shown that TGFb1, IL-1, and
IL-8 induce changes that may be related to androgen
independence.14,18,19
Furthermore, we identified a thought-provoking
correlation between race and anemia. In a multivari-
ate analysis, African-American race alone was not a
strong predictor of death or disease progression.
However, our results suggest that the effect of base-
line hemoglobin level on overall and progression-free
survival varied significantly by race. Overall, anemic
African Americans fared worse than anemic Cauca-
sians, and African Americans with high baseline
hemoglobin fared better than Caucasians with simi-
lar hemoglobin levels.
The racial disparity in prostate cancer outcomes
is well described. African Americans are at greater
risk of being diagnosed with the disease,20 have
higher risk disease at diagnosis,21,22 and, overall, have
a higher risk of dying from prostate cancer.20 Gener-
ally, it is believed that the differences in prostate
cancer outcomes are explained by disease-related
factors. After correcting for stage, grade, and other
known prognostic factors, race generally is not pre-
dictive of worse outcomes in men with prostate can-
cer. This has been demonstrated in studies of
clinically localized prostate cancer23–25 and meta-
static disease. Analyses of 5284 men with newly diag-
nosed, primarily distant-stage disease26 and of 1183
patients with metastatic, hormone-refractory dis-
ease27 showed no independent effect of race on sur-
vival. Although a previous analysis of SWOG 8894
identified a significant race effect,28 hemoglobin data
were unavailable at that time. In the current analysis
of SWOG 8894, we observed that, after adjusting for
both baseline hemoglobin and 3-month change in
hemoglobin, race no longer was an adverse prognos-
tic factor.
Thus, the complex relation between baseline
anemia, race, and survival identified here is unex-
pected and novel. Although our study was not de-
signed to determine the underlying cause for the
observed anemia-race interaction, several hypotheses
may be considered. Prior analyses showed that Afri-
can-American men who presented with either hor-
mone-naive or hormone-resistant, metastatic prostate
cancer had lower hemoglobin concentrations than
their Caucasian counterparts.1,27 Healthy African
Americans also had significantly lower mean concen-
trations of hemoglobin than Caucasians.29 These dis-
crepancies may be explained by a higher prevalence
of hemoglobinopathies30,31 and by a higher incidence
of folate deficiency32 among African Americans.
The prevalence of sickle cell trait among African
Americans is between 8% and 10%.33 Although this is
a clinically benign carrier trait, little is known about
the impact of sickle cell trait on tumor hypoxia. A
single case study of a sickle trait carrier with squa-
mous cell carcinoma of the cervix demonstrated
extensive intratumoral sickling and tumor hypoxia.34
To the best of our knowledge, no other studies have
examined the possibility that otherwise benign hemo-
globin abnormalities may exacerbate tumor hypoxia
and, consequently, promote tumor resistance to ther-
apy. Another hypothesis worthy of consideration is
that there may be race-specific differences in pros-
tate cancer hypoxic response. For example, in a study
of 223 patients, the patterns of expression of N-myc
downstream-regulated gene-1 (NDRG1), a hypoxia-
related and androgen-regulated gene, differed signifi-
cantly between African Americans and Caucasians.35
It also is possible that the pathophysiology of
cancer-related anemia may differ across races. For
example, if African Americans were less susceptible
to developing cancer-associated anemia, then it
would be expected that the same degree of anemia
would be associated with more severe disease in Afri-
can Americans. We are not aware of data that
address this question, although functional poly-
morphisms of many of the cytokines that are impor-
tant in the anemia of chronic disease have been
described. A number of investigators have found dif-
ferences in racial distributions of these polymorph-
isms. For example, Ness et al. reported that
polymorphisms known to increase expression of
proinflammatory cytokines IL-1A, IL-1B, IL-18, and
IL-6 were significantly more likely to be expressed in
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African-American women than in white women.36 In
another study, it was observed that individuals of
African descent predominantly carried low-producing
IL-10 alleles and high-producing IL-6 alleles.37 If dif-
ferences in the racial distribution of gene poly-
morphisms that regulate the development of cancer-
associated anemia exist, then such differences may
explain the complex relation between anemia, race,
and outcome observed in this study.
In summary, our data extend previous findings
that link anemia with poor outcomes in men with
advanced prostate cancer. We observed that, in addi-
tion to baseline anemia, a decline in hemoglobin
after 3 months of ADT was associated independently
with shorter progression-free and overall survival.
Furthermore, we identified an unexpected, complex
interaction between race, anemia, and progression-
free and overall survival in men with advanced pros-
tate cancer. Although these findings provide impor-
tant new information about prognosis in patients
with advanced prostate cancer, they should not be
interpreted as supportive of the therapeutic correc-
tion of anemia to improve outcome. It is not known
whether anemia-directed interventions in these
patients can modify the association between baseline
anemia, 3-month hemoglobin decline, and patient
outcomes. Further investigation of anemia and out-
comes in patients with prostate cancer should be
pursued, and prospective clinical trials of anemia
correction during hormone therapy should be con-
sidered.
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